BioCentury | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

...inhibitors include Tarceva erlotinib from Astellas Pharma Inc. (Tokyo:4503) and AZ’s Tagrisso osimertinib and Iressa gefitinib...
BioCentury | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

...by MNCs: AstraZeneca plc (LSE:AZN; NYSE:AZN) won a bid for its lung cancer drug Iressa gefitinib...
...price cut. Both companies won their national bids at the same discount. AZ shares the gefitinib...
BioCentury | Sep 25, 2019
Politics & Policy

China moves to take centralized procurement nationwide

...were from MNCs: AstraZeneca plc (LSE:AZN; NYSE:AZN) won a bid for lung cancer drug Iressa gefitinib...
...won the bid for hypertension drug Monopril fosinopril with a 70% price cut. AZ's 2Q19 Iressa...
...second batch of drugs added to the program that year. Hongjiang Li, Staff Writer Fosinopril, Monopril Iressa, gefitinib (ZD1839) Lipitor...
BioCentury | Sep 20, 2019
Company News

China exempts 12 cancer drugs from tariffs

...offered tariff relief since the trade war began last year. The 12 drugs include Iressa gefitinib...
...cytarabine. Some of the products are big sellers in China for global pharmas. AZ’s 2Q19 Iressa...
...Tariffs already imposed will be refunded. Mary Romeo, Assistant Editor and Hongjiang Li, Staff Writer Iressa, gefitinib (ZD1839) Xeloda...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...EGFR inhibitor Iressa gefitinib from AstraZeneca. Novartis is testing capmatinib with Roche’s Tarceva erlotinib and Iressa...
BioCentury | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

...liver cancer. Other small molecule EGFR inhibitors marketed for oncology indications include AstraZeneca plc’s Iressa gefitinib...
BioCentury | Aug 9, 2019
Clinical News

AZ notches another win in cancer with Tagrisso in NSCLC

...enrolled 556 patients who received Tagrisso or competing oral EGFR inhibitors Tarceva erlotinib or Iressa gefitinib...
BioCentury | Jun 19, 2019
Regulation

Why China’s 4 + 7 policy is good news for innovative drug developers

...winning bids were from multinationals: AstraZeneca plc won a bid for lung cancer drug Iressa gefitinib...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

...first-generation EGFR-inhibitor Iressa gefitinib to determine if it can delay the onset of resistance to Iressa...
...completion date for the Tagrisso combination study is June 2021, and March 2021 for the Iressa...
BioCentury | Apr 22, 2019
Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

...xenograft mouse models of dual-mutant PDAC, two shRNA against RAF1 plus the EGFR inhibitors Iressa gefitinib...
...CRAF inhibitors in combination with EGFR inhibitors in KRAS- and p53-mutant PDAC. AstraZeneca plc markets Iressa...
Items per page:
1 - 10 of 370